Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Published Online: 2020-09-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Alexander L Gintsburg•Alexander S Semikhin•Alina S Dzharullaeva•Alina S Erokhova•Amir I Tukhvatulin•Andrei G Botikov•Anna V Kovyrshina•Boris S Naroditsky•Daria A Egorova•Daria M Grousova•Daria V Voronina•Denis I Zrelkin•Denis Y Logunov•Dmitry N Shcherbinin•Dmitry V Shcheblyakov•Elena A Smolyarchuk•Elizaveta A Tokarskaya•Evgeny V Kryukov•Fatima M Izhaeva•Ilias B Esmagambetov•Inna V Dolzhikova•Irina A Favorskaya•Lola F Morozova•Maksim M Shmarov•Nadezhda L Lubenets•Natalia A Nikitenko•Olga Popova•Olga V Zubkova•Sergei V Borisevich•Tatiana A Ozharovskaya•Vladimir F Babira•Yana V Simakova
